Vincristine News and Research

RSS
Vincristine is the active ingredient in a drug used to treat acute leukemia. It is used in combination with other drugs to treat Hodgkin disease, non-Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms tumor. Vincristine is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division. It is a type of vinca alkaloid and a type of antimitotic agent.
Study shows both IDH-mutant WHO-defined molecular subgroups could benefit from PCV chemoradiotherapy

Study shows both IDH-mutant WHO-defined molecular subgroups could benefit from PCV chemoradiotherapy

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Pediatric neuroblastoma patients have high risk of long-term psychological impairment

Pediatric neuroblastoma patients have high risk of long-term psychological impairment

Study shows new approach to improve survival rates for patients with stage IV Wilms tumors

Study shows new approach to improve survival rates for patients with stage IV Wilms tumors

HDAC6 inhibition could be promising therapeutic approach for peripheral neuropathies

HDAC6 inhibition could be promising therapeutic approach for peripheral neuropathies

Clearance of cancer cell debris via pro-resolving mediators can prevent tumor recurrence

Clearance of cancer cell debris via pro-resolving mediators can prevent tumor recurrence

Novel agents appear to halt growth and progression of Ewing sarcoma

Novel agents appear to halt growth and progression of Ewing sarcoma

St. Jude creates world’s largest collection of pediatric solid tumor samples

St. Jude creates world’s largest collection of pediatric solid tumor samples

HHMI scientists expand access to new resource for studying pediatric cancers

HHMI scientists expand access to new resource for studying pediatric cancers

Study finds no clear benefit of stem-cell transplant for double-hit lymphoma patients in remission

Study finds no clear benefit of stem-cell transplant for double-hit lymphoma patients in remission

Feinstein Institute research may lead to new treatment option for low-grade gliomas

Feinstein Institute research may lead to new treatment option for low-grade gliomas

New research reveals surprising culprit involved in self-destruction of axons

New research reveals surprising culprit involved in self-destruction of axons

Scientists discover genomic alterations in pediatric relapsed ALL

Scientists discover genomic alterations in pediatric relapsed ALL

Researchers identify higher risk of early chemotherapy-related death in older patients with DLBCL

Researchers identify higher risk of early chemotherapy-related death in older patients with DLBCL

Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

Radiation plus chemotherapy improves survival of low-grade brain cancer patients

Radiation plus chemotherapy improves survival of low-grade brain cancer patients

Radiation therapy plus PCV chemotherapy improves survival of low-grade glioma patients

Radiation therapy plus PCV chemotherapy improves survival of low-grade glioma patients

Abnormal breakage of chromosomes in white blood cells triggers aggressive form of ALL

Abnormal breakage of chromosomes in white blood cells triggers aggressive form of ALL

Positive bosutinib response for elderly blast phase CML patient

Positive bosutinib response for elderly blast phase CML patient